bekhterevОбозрение психиатрии и медицинской психологии имени В.М.БехтереваV.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY2313-70532713-055XV. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH10.31363/2313-7053-2025-2-1147bekhterev-1162Research ArticleВ ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУGUIDELINES FOR THE PRACTITIONERПрименение антипсихотиков третьего поколения в сочетании с клозапином при терапии резистентной шизофренииUse of third-generation antipsychotics in combination with clozapine in the treatment of resistant schizophreniahttps://orcid.org/0000-0001-7148-4485АсадуллинА. Р.AsadullinA. R.

Асадуллин Азат Раилевич — доктор медицинских наук, профессор кафедры наркологии ФГБОУ ДПО РМАНПО Минздрава России; профессор кафедры психиатрии, наркологии и психотерапии ФГБОУ ВО Башкирский государственный медицинский университет МЗ РФ); профессор кафедры психиатрии, наркологии, психотерапии и клинической психологии ФГБОУ ВО «Саратовский Государственный медицинский университет имени В.И. Разумовского Минздрава РФ»; профессор кафедры Психиатрии и наркологии Ташкентской Медицинской Академии

109390, г. Москва, ул. Люблинская, 37/1

Республика Башкортостан, 450008, г. Уфа, ул. Ленина, 3

410012, г. Саратов, ул. Большая Казачья, 112

Узбекистан, 100109, г. Ташкент, ул. Фаробий, 2

Azat R. Asadullin 

Uf

droar@yandex.ruhttps://orcid.org/0009-0006-7559-2719БомовП. О.BomovP. O.

Бомов Павел Олегович — кандидат медицинских наук, доцент, эксперт Росздравнадзора по вопросам психиатрии, психиатрии-наркологии, психотерапии и сексологии по Санкт-Петербургу и Ленинградской области., и.о. заведующего кафедрой психотерапии, медицинской психологии и сексологии

195067, г. Санкт-Петербург, пр. Пискаревский, 47

Pavel O. Bomov 

St. Petersburg

bomoff@yandex.ruhttps://orcid.org/0009-0006-0496-284XБогодЮ. А.BogodYu. A.

Богод Юлия Алексеевна — ординатор по специальности «психиатрия»

195067, г. Санкт-Петербург, пр. Пискаревский, 47

Yulia A. Bogod

St. Petersburg

jubogod@gmail.comБашкирский государственный медицинский университетРоссияBashkir State Medical UniversityRussian FederationСеверо-Западный государственный медицинский университет им. И.И. МечниковаРоссияNorth-Western State Medical University named after I.I. MechnicovRussian Federation202530062025592114121Copyright © Асадуллин А.Р., Бомов П.О., Богод Ю.А., 20252025Асадуллин А.Р., Бомов П.О., Богод Ю.А.Asadullin A.R., Bomov P.O., Bogod Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.bekhterevreview.com/jour/article/view/1162

Целью исследования являлся анализ патогенеза и стратегий терапии резистентной шизофрении путем поиска, выбора и обзора публикаций, освещающих данную тему. В ходе работы было проанализировано 42 статьи, в результате чего удалось сделать вывод об эффективности и хорошей переносимости антипсихотиков третьего поколения у пациентов с резистентной шизофренией, принимающих клозапин, а также сформулировать заключение, что антипсихотики третьего поколения могут быть эффективны в таких случаях.

The aim of the study was to analyze the pathogenesis and treatment strategies of treatment-resistant schizophrenia by searching, selecting and reviewing publications covering this topic. 42 articles were analyzed during the work, which contributed to the conclusion about the effectiveness and good tolerability of third-generation antipsychotics in patients with resistant schizophrenia taking clozapine, and also to formulate the conclusion that third-generation antipsychotics can be effective in such cases.

«шизофрения»«аугментация»«брексипипразол»«арипипразол»«карипразин»«клозапин»«schizophrenia»«augmentation»«brexipiprazol»«aripiprazol»«cariprazine»«clozapin»ReferencesДорофейкова М.В., Петрова Н.Н. Персонализированный подход к терапии депрессии при шизофрении. Современная терапия психических расстройств. 2021;3:39-46.Dorofeykova MV, Petrova NN. Personalized approach to the treatment of depression in schizophrenia. Sovremennaya terapiya psihicheskih rasstrojstv. 2021;3:39-46. (In Russ.).Коцюбинский А.П. Исаенко Ю.В., Протасов А.Р., Бутома Б.Г., Степанова А.В., Степанова А.А. Дифференцированный подход к терапии шизотипического расстройства. Диагностика и лечение психических и наркологических расстройств: современные подходы. Сборник методических рекомендаций. Сост. Н.В. Семенова, под общ. ред. Н.Г. Незнанова. Выпуск 7. — СПб.: Издательско- полиграфическая компания «КОСТА», 2024.Kotsyubinskij A.P. Isaenko Yu.V., Protasov A.R., Butoma B.G., Stepanova A.V., Stepanova A.A. Differencirovannyj podhod k terapii shizotipicheskogo rasstrojstva. Diagnostika i lechenie psihicheskih i narkologicheskih rasstrojstv: sovremennye podhody. Sbornik metodicheskih rekomendacij. Sost. N.V. Semenova, pod obshch. red. N.G. Neznanova. Vypusk 7. — SPb.: Izdatel’sko- poligraficheskaya kompaniya «KOSTA», 2024. (In Russ.).Сычев Д.А., Отделёнов В.А., Краснова Н.М., Ильина Е.С. Полипрагмазия: взгляд клинического фармаколога. Терапевтический архив. 2016;88(12):94102. DOI: 10.17116/terarkh2016881294-102Sychev DA, Otdelеnov VA, Krasnova NM, Il’ina ES. Polypragmasy: A clinical pharmacologist’s view. Terapevticheskij arhiv. 2016;88(12):94102. (In Russ.). DOI: 10.17116/terarkh2016881294-102Chakrabarti S. Clozapine resistant schizophrenia: newer avenues of management. World Journal of Psychiatry. 2021;11(8):429. DOI: 10.5498/wjp.v11. i8.429Chakrabarti S. Clozapine resistant schizophrenia: newer avenues of management. World Journal of Psychiatry. 2021;11(8):429. DOI: 10.5498/wjp.v11. i8.429Chan SKW et al. Predictors of treatment-resistant and clozapine-resistant schizophrenia: a 12year follow-up study of first-episode schizophrenia-spectrum disorders. Schizophrenia bulletin. 2021;47(2):485-494. DOI: 10.1093/schbul/sbaa145Chan SKW et al. Predictors of treatment-resistant and clozapine-resistant schizophrenia: a 12year follow-up study of first-episode schizophrenia-spectrum disorders. Schizophrenia bulletin. 2021;47(2):485-494. DOI: 10.1093/schbul/sbaa145Chan SKW et al. Clozapine dosing patterns and clinical outcomes in patients with treatment resistant schizophrenia. European Neuropsychopharmacology. 2023;75:67-79. DOI: 10.1016/j.euroneuro.2023.07.007Chan SKW et al. Clozapine dosing patterns and clinical outcomes in patients with treatment resistant schizophrenia. European Neuropsychopharmacology. 2023;75:67-79. DOI: 10.1016/j.euroneuro.2023.07.007Dionisie V. Clozapine—serious adverse effects and clinical management. Antidotes to Toxins and Drugs. Imprint: Elsevier, 2024.Dionisie V. Clozapine—serious adverse effects and clinical management. Antidotes to Toxins and Drugs. Imprint: Elsevier, 2024.Diniz E et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Brazilian Journal of Psychiatry. 2023;45(5):448458. DOI: 10.47626/1516-4446-2023-3126Diniz E et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Brazilian Journal of Psychiatry. 2023;45(5):448458. DOI: 10.47626/1516-4446-2023-3126Dmuhovskis A, Taube M. Cariprazine and clozapine combination for the treatment of psychosis in a young, female patient with schizophrenia: a case report. Frontiers in Psychiatry. 2024;15:52-80.Dmuhovskis A, Taube M. Cariprazine and clozapine combination for the treatment of psychosis in a young, female patient with schizophrenia: a case report. Frontiers in Psychiatry. 2024;15:52-80.Efthimiou O et al. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data. The Lancet Psychiatry. 2024;11(2):102-111. DOI: 10.1016/S2215-0366(23)00366-8Efthimiou O et al. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data. The Lancet Psychiatry. 2024;11(2):102-111. DOI: 10.1016/S2215-0366(23)00366-8Egyed A., Kiss D.J., Keserű G.M. The Polypharmacology of Cariprazine and its Implications to Clinical Indications. Polypharmacology: Strategies for Multi‐Target Drug Discovery. 2025.Egyed A., Kiss D.J., Keserű G.M. The Polypharmacology of Cariprazine and its Implications to Clinical Indications. Polypharmacology: Strategies for Multi‐Target Drug Discovery. 2025.Esposito CM et al. Gender differences in clinical and biochemical parameters among patients hospitalized for schizophrenia: towards precision medicine. European Archives of Psychiatry and Clinical Neuroscience. 2024;274(5):1093-1103. DOI: 10.1007/s00406-023-01644-4Esposito CM et al. Gender differences in clinical and biochemical parameters among patients hospitalized for schizophrenia: towards precision medicine. European Archives of Psychiatry and Clinical Neuroscience. 2024;274(5):1093-1103. DOI: 10.1007/s00406-023-01644-4Freibüchler A, Seifert R. Analysis of clinical studies on clozapine from 2012-2022. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(12):9745-9765. DOI: 10.1007/s00210-024-03209-1Freibüchler A, Seifert R. Analysis of clinical studies on clozapine from 2012-2022. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(12):9745-9765. DOI: 10.1007/s00210-024-03209-1Generoso MB et al. Cariprazine for treating psychosis: an updated meta-analysis. International Journal of Psychiatry in Clinical Practice. 2023;27(1):107-109. DOI: 10.1080/13651501.2022.2071740Generoso MB et al. Cariprazine for treating psychosis: an updated meta-analysis. International Journal of Psychiatry in Clinical Practice. 2023;27(1):107-109. DOI: 10.1080/13651501.2022.2071740Hart XM et al. Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis. Psychopharmacology. 2022;239(11):3377-3391. DOI: 10.1007/s00213-022-06233-2Hart XM et al. Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis. Psychopharmacology. 2022;239(11):3377-3391. DOI: 10.1007/s00213-022-06233-2Howes OD, Bukala BR, Beck K. Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nature Reviews Neurology. 2024;20(1):2235. DOI: 10.1038/s41582-023-00904-0Howes OD, Bukala BR, Beck K. Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nature Reviews Neurology. 2024;20(1):2235. DOI: 10.1038/s41582-023-00904-0Legge SE et al. Clinical indicators of treatment-resistant psychosis. The British Journal of Psychiatry. 2020;216(5):259-266. DOI: 10.1192/bjp.2019.120Legge SE et al. Clinical indicators of treatment-resistant psychosis. The British Journal of Psychiatry. 2020;216(5):259-266. DOI: 10.1192/bjp.2019.120McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA Psychiatry United States. 2020;77:201–10. DOI: 10.1001/jamapsychiatry.2019.3360McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA Psychiatry United States. 2020;77:201–10. DOI: 10.1001/jamapsychiatry.2019.3360Jiang Y et al. Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. Journal of Affective Disorders. 2024;346:223-229.Jiang Y et al. Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. Journal of Affective Disorders. 2024;346:223-229.Li Y et al. Predictors of functioning in treatment-resistant schizophrenia: the role of negative symptoms and neurocognition. Frontiers in Psychiatry. 2024;15:1444843. DOI: 10.3389/fpsyt.2024.1444843Li Y et al. Predictors of functioning in treatment-resistant schizophrenia: the role of negative symptoms and neurocognition. Frontiers in Psychiatry. 2024;15:1444843. DOI: 10.3389/fpsyt.2024.1444843Luykx JJ et al. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry. 2023;10(8):644-652. DOI: 10.1016/S2215-0366(23)00109-8Luykx JJ et al. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry. 2023;10(8):644-652. DOI: 10.1016/S2215-0366(23)00109-8Mohr P, Masopust J, Kopeček M. Dopamine receptor partial agonists: Do they differ in their clinical efficacy? Frontiers in Psychiatry. 2022;12:19-46. DOI: 10.3389/fpsyt.2021.781946Mohr P, Masopust J, Kopeček M. Dopamine receptor partial agonists: Do they differ in their clinical efficacy? Frontiers in Psychiatry. 2022;12:19-46. DOI: 10.3389/fpsyt.2021.781946Németh G et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. The Lancet. 2017;389(10074):1103-1113. DOI: 10.1016/S0140-6736(17)30060-0Németh G et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. The Lancet. 2017;389(10074):1103-1113. DOI: 10.1016/S0140-6736(17)30060-0Nucifora Jr FC et al. Clozapine as a model for antipsychotic development. Neurotherapeutics.2017;14(3):750-761. DOI: 10.1007/s13311-017-0552-9Nucifora Jr FC et al. Clozapine as a model for antipsychotic development. Neurotherapeutics.2017;14(3):750-761. DOI: 10.1007/s13311-017-0552-9Ortiz BB et al. A symptom combination predicting treatment-resistant schizophrenia–A strategy for real-world clinical practice. Schizophrenia research. 2020;218:195-200. DOI: 10.1016/j.schres.2020.01.002Ortiz BB et al. A symptom combination predicting treatment-resistant schizophrenia–A strategy for real-world clinical practice. Schizophrenia research. 2020;218:195-200. DOI: 10.1016/j.schres.2020.01.002Panov G. Gender-associated role in patients with schizophrenia. Is there a connection with the resistance? Frontiers in Psychiatry. 2022;13:54-55. DOI: 10.3389/fpsyt.2022.995455Panov G. Gender-associated role in patients with schizophrenia. Is there a connection with the resistance? Frontiers in Psychiatry. 2022;13:54-55. DOI: 10.3389/fpsyt.2022.995455Pappa S et al. Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study. Therapeutic Advances in Psychopharmacology. 2022;12:45-53. DOI: 10.1177/20451253221132087Pappa S et al. Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study. Therapeutic Advances in Psychopharmacology. 2022;12:45-53. DOI: 10.1177/20451253221132087Petric D. Drug Interactions and Drug Interaction Checkers. Academia Letters. 2021.Petric D. Drug Interactions and Drug Interaction Checkers. Academia Letters. 2021.Pirc Marolt T et al. Aripiprazole reduces liver cell division. Plos one. 2020;15(10):24-54.Pirc Marolt T et al. Aripiprazole reduces liver cell division. Plos one. 2020;15(10):24-54.Rantala MJ et al. Schizophrenia: The new etiological synthesis. Neuroscience & Biobehavioral Reviews. 2022;142:104894. DOI: 10.1016/j.neubiorev.2022.104894Rantala MJ et al. Schizophrenia: The new etiological synthesis. Neuroscience & Biobehavioral Reviews. 2022;142:104894. DOI: 10.1016/j.neubiorev.2022.104894Ricci V et al. Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: efficacy, safety, and cognitive impacts. A narrative review. International Clinical Psychopharmacology. 2024;10-97.Ricci V et al. Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: efficacy, safety, and cognitive impacts. A narrative review. International Clinical Psychopharmacology. 2024;10-97.Seppälä A et al. Predictors of response to pharmacological treatments in treatment-resistant schizophrenia — a systematic review and meta-analysis. Schizophrenia Research. 2021;236:123-134. DOI: 10.1016/j.schres.2021.08.005Seppälä A et al. Predictors of response to pharmacological treatments in treatment-resistant schizophrenia — a systematic review and meta-analysis. Schizophrenia Research. 2021;236:123-134. DOI: 10.1016/j.schres.2021.08.005Schulte PFJ et al. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: can the regulations be relaxed? Schizophrenia Research. 2024;268:74-81. DOI: 10.1016/j.schres.2023.09.024Schulte PFJ et al. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: can the regulations be relaxed? Schizophrenia Research. 2024;268:74-81. DOI: 10.1016/j.schres.2023.09.024Siskind D et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. The British Journal of Psychiatry. 2022;220(3):115-120. DOI: 10.1192/bjp.2021.61Siskind D et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. The British Journal of Psychiatry. 2022;220(3):115-120. DOI: 10.1192/bjp.2021.61Siwek M et al. Cariprazine augmentation of clozapine in schizophrenia—a retrospective chart review. Frontiers in Pharmacology. 2024;14:112 -132. DOI: 10.3389/fphar.2023.1321112Siwek M et al. Cariprazine augmentation of clozapine in schizophrenia—a retrospective chart review. Frontiers in Pharmacology. 2024;14:112 -132. DOI: 10.3389/fphar.2023.1321112Smart SE et al. Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. Psychological medicine. 2021;51(1):44-53. DOI: 10.1017/S0033291719002083Smart SE et al. Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. Psychological medicine. 2021;51(1):44-53. DOI: 10.1017/S0033291719002083Tandon R et al. The schizophrenia syndrome, circa 2024: What we know and how that informs its nature. Schizophrenia research. 2024;264:1-28. DOI: 10.1016/j.schres.2023.11.015Tandon R et al. The schizophrenia syndrome, circa 2024: What we know and how that informs its nature. Schizophrenia research. 2024;264:1-28. DOI: 10.1016/j.schres.2023.11.015Terao I, Kodama W. Comparative Efficacy of Dopamine Partial Agonists by Doses for Treat- ment-Resistant Depression: A Systematic Review and Dose-Response Model-Based Network Meta-analysis. Journal of Clinical Psychopharmacology. 2024;44(4):413-417. DOI: 10.1097/JCP.0000000000001862Terao I, Kodama W. Comparative Efficacy of Dopamine Partial Agonists by Doses for Treat- ment-Resistant Depression: A Systematic Review and Dose-Response Model-Based Network Meta-analysis. Journal of Clinical Psychopharmacology. 2024;44(4):413-417. DOI: 10.1097/JCP.0000000000001862Van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int Pharmacodyn Ther. 1996;160:492-494.Van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int Pharmacodyn Ther. 1996;160:492-494.Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence? Frontiers in psychiatry. 2022;13:94-106. DOI: 10.3389/fpsyt.2022.1069432Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence? Frontiers in psychiatry. 2022;13:94-106. DOI: 10.3389/fpsyt.2022.1069432Wagner E et al. Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review. Translational psychiatry. 2021;11(1):487. DOI: 10.1038/s41398-021-01613-2Wagner E et al. Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review. Translational psychiatry. 2021;11(1):487. DOI: 10.1038/s41398-021-01613-2Wesley EW et al. Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register. Schizophrenia Research. 2021;232:6876. DOI: 10.1016/j.schres.2021.05.006Wesley EW et al. Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register. Schizophrenia Research. 2021;232:6876. DOI: 10.1016/j.schres.2021.05.006

The authors declare that there are no conflicts of interest present.